Why Cingulate Inc.’s (CING) Stock Is Down 6.52%
As of Monday, July 13, Cingulate Inc.’s CING share price has dipped by 6.52%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Commentary & Analysis
Why Cingulate Inc.’s (CING) Stock Is Down 6.23%
As of Tuesday, July 07, Cingulate Inc.’s CING share price has dipped by 6.23%, which has investors questioning if this is right time to buy.Michael Rose
Why Cingulate Inc.’s (CING) Stock Is Down 6.79%
As of Thursday, July 02, Cingulate Inc.’s CING share price has dipped by 6.79%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Cingulate Inc.’s (CING) Stock Is Up 9.92%
As of Wednesday, June 17, Cingulate Inc.’s CING share price has surged by 9.92%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Cingulate Inc.’s (CING) Stock Is Up 10.55%
As of Wednesday, June 17, Cingulate Inc.’s CING share price has surged by 10.55%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | CING | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $64.5 | $579.1 | 18% |
|
| Shares Out (Mil) | 9.8 | 43.0 | 20% |
|
| Institutional Ownership | 96.5% | 84.3% | 70% |
|
| Float (Mil) | 13.1 | 46.8 | 23% |
|
| Beta | -0.81 | 0.62 | 1% |
|
| Avg Daily Volume (000s) | 134 | 285 | 39% |
|
| Price Change (52-week) |
(7.7%) | 63.8% | 39% |
|
| Growth | CING | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | (25.5%) | (1.4%) | 16% |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (14.9%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 4 | 4 | |
| Current EPS | ($0.563) | ($2.300) | ($0.740) | |
| Month Ago EPS | ($0.563) | ($2.300) | ($0.740) | |
| # Rev Up | 2 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.517) | ($1.878) | ($1.455) | |
| Year/Year Chg | (40.9%) | (48.2%) | (76.1%) | |
| Financials | CING | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $272 | na |
|
| Net Income (TTM) (Mil) | ($28) | ($11) | 21% |
|
| EPS (TTM) | ($4.236) | ($0.500) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($20) | ($6) | 15% |
|
| Net Cash Flow (TTM) (Mil) | $16 | $4 | 61% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $7 | 17% |
|
| Enterprise Value (Q1) (Mil) | $45 | $522 | 15% |
|
| Valuation | CING | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.03 | 2.73 | 65% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | CING | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | 0.7% | na |
|
| ROA | (128.8%) | (24.6%) | 4% |
|
| ROE | (225.1%) | (19.7%) | 4% |
|
| Liabilities to Assets | 38.9% | 35.5% | 29% |
|
| F-Score | 4 | 3 | 34% |
|
Cingulate Inc. did not pass any screens on 7/31/2026.
